Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Controlled, Phase 2/3 Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia

NCT04102501 is registered in ClinicalTrials.gov with Biojiva LLC as lead sponsor.

NCT NCT04102501
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04102501 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Controlled, Phase 2/3 Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia
Lead sponsor
Biojiva LLC
Phase
Phase 3
Overall status
Completed
Start date
October 30, 2019
Completion date
August 23, 2021
Enrollment
65 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

friedreich's ataxia